Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavorixafor - X4 Pharmaceuticals

X
Drug Profile

Mavorixafor - X4 Pharmaceuticals

Alternative Names: ABSK-081; AMD-070; AMD-11070; X4P 001 RD; X4P-001; X4P-001-IO; XOLREMDI

Latest Information Update: 04 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnorMED
  • Developer Abbisko Therapeutics; X4 Pharmaceuticals
  • Class Antineoplastics; Antiretrovirals; Benzimidazoles; Diamines; Hydroquinones; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - WHIM syndrome; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered WHIM syndrome
  • Phase III Neutropenia
  • Phase I/II Triple negative breast cancer
  • Discontinued HIV-1 infections; Malignant melanoma; Renal cell carcinoma; Solid tumours; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 27 Jun 2024 Phase-III clinical trials in Neutropenia (In adolescents, In adults, In the elderly) in Georgia (PO) (NCT06056297)
  • 27 Jun 2024 Adverse events and efficacay data from a phase I/II trial in Chronic neutropenia released by X4 Pharmaceuticals
  • 07 May 2024 X4 Pharmaceuticals announces intention to submit regulatory application to European Medicines Agency (EMA) for WHIM syndrome in late 2024 or early 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top